REG - Genflow Biosciences - Exercise of Warrants and Issue of Equity

Genflow BiosciencesAnnouncement

08/05/2026 10:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260508:nRSH6179Da&default-theme=true

RNS Number : 6179D  Genflow Biosciences PLC  08 May 2026

8 May 2026

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Genflow Biosciences Plc

("Genflow" or the "Company")

Exercise of Warrants and Issue of Equity

Genflow (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a
biotechnology company focused on the development of gene therapies for
age-related diseases announces that it has received notices of exercise of
warrants for a total of 30,756,577 new ordinary shares in the capital of the
Company (the "Warrant Shares") with gross proceeds amounting to £359,374.99.

The Warrant Shares comprise:

·    2,631,578 new ordinary shares being issued pursuant to the exercise
of warrants granted and announced on 5 March 2026. Each warrant entitles the
holder to subscribe for one new ordinary share at an exercise price of 1.9p
per share. Subscription monies of £49,999.99 have been received by the
Company in respect of the full exercise of these warrants.

·    28,124,999 new ordinary shares being issued pursuant to the exercise
of warrants granted and announced on 8 May 2025. As announced, the exercise
price of these warrants ("Exercise Price") is subject to adjustment in certain
circumstances, as set out in the warrant instrument, including a reset of the
Exercise Price (as defined therein) if the Company completes a share issuance
(or other transaction granting rights to subscribe for equity securities)
during the Exercise Period (as defined therein) at a price lower than the
Exercise Price. As such, the Exercise Price was adjusted to 1.1p. Subscription
monies of £309,375 have been received by the Company in respect of this
exercise.

Admission and Total Voting Rights

Application has been made for the Warrant Shares, which will rank pari
passu in all respects with the existing Ordinary Shares of the Company, to be
admitted to the FCA official list and to trading on the equity shares
(transition) category of the Official List maintained by the FCA and to
trading on the main market for listed securities of the LSE, which is expected
to occur on or around 8.00 a.m. on 13 May 2026 ("Admission").

The total number of issued shares and the total number of voting rights in the
Company, following Admission, will be 566,409,782.

The above figure of 566,409,782 should be used by shareholders in the Company
as the denominator for the calculations by which they will determine if they
are required to notify their interest in, or a change to their interest in,
the share capital of the Company, under the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules.

Enquiries:

 Genflow Biosciences Plc                 https://genflowbio.com
 Dr Eric Leire, Chief Executive Officer  +32 4774 95881
 Harbor Access                           Tel: +44 (0)20 3470 0470
 Jonathan Paterson, Investor Relations   +1 475 477 9401
                                         Jonathan.Paterson@harbor-access.com

About Genflow Biosciences Plc

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies for age-related diseases, with the goal
of promoting longer and healthier lives while mitigating the financial,
emotional, and social impacts of a fast-growing aging global population.
Genflow's lead compound, GF-1002, works through the delivery of a centenarian
variant of the SIRT6 gene which has yielded promising preclinical results.
Genflow's proof-of-concept clinical trial evaluating its SIRT6-centenarian
gene therapy in aged dogs began in March 2025. Other programs include a
clinical trial that will explore the potential benefits of GF-1002 in treating
MASH (Metabolic Dysfunction Associated Steatohepatitis), the most prevalent
chronic liver disease for which there is no effective treatments. Please visit
www.genflowbio.com (http://www.genflowbio.com)   and follow the Company on
LinkedIn
(https://www.linkedin.com/company/genflow-biosciences/?viewAsMember=true) and
X (https://x.com/genflowbio) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEEANSPEEDKEEA



            Copyright 2019 Regulatory News Service, all rights reserved